MA-WASABI/ZERO-CIRCLE
Zero Circle, a sustainable finance marketplace, and Wasabi Technologies, the hot cloud storage company, have partnered to develop a suite of sustainability-focused solutions for cloud storage that give businesses the data they need to make decisions that reduce their environmental impact.
Wasabi cloud storage integrated Zero Circle’s invoice-based carbon footprint calculator to give customers transparency and real-time assessment of their carbon footprint. Customers can upload their Wasabi invoice to Zero Circle’s carbon calculator to determine their estimated CO2 footprint based on actual data stored in a Wasabi storage region, increasing the accuracy of their ESG benchmarking with their peers and helping them make more sustainable business decisions.
According to the Wasabi 2024 Global Cloud Storage Index, sustainability ranks among the top three most important considerations for buyers when choosing a cloud storage service. Factors like ESG commitments, energy-efficient architecture design, and native tools for carbon footprint calculation are all increasingly important to modern enterprises as they adopt cloud infrastructure services. As a result, the survey found that cloud service providers must deliver accurate, reliable tools, metrics, and programs to meet customer expectations.
This joint initiative leverages Zero Circle's deep expertise in sustainability and product carbon footprint measurement with Wasabi's leadership in cloud storage to drive sustainability in the cloud storage industry and create innovative solutions that support businesses with their sustainability initiatives. The solution's unique features and flexibility make it a powerful resource for companies seeking to measure and track their cloud sustainability, such as real-time emissions calculations integrated directly into the purchases from supply chain partners.
“Partnering with Zero Circle underscores Wasabi’s dedication to providing top-tier, sustainable cloud storage solutions,” said David Boland, vice president of cloud strategy at Wasabi Technologies. “Zero Circle's carbon footprint calculation has already enabled Wasabi, our partners, and customers to gain a deeper understanding of our environmental impact. By integrating this solution into our supply chain, we are amplifying these benefits for everyone involved.”
"Announcing our collaboration with Wasabi marks a significant step in advancing environmental sustainability within the cloud storage sector,” said Hemanth Setty, founder and CEO of Zero Circle. “This partnership leverages our combined strengths and underscores our mutual dedication to fostering a more sustainable future, paving the way for innovative and groundbreaking solutions.”
The carbon footprint solution is now available to all Wasabi customers. The Zero Circle – Wasabi collaboration will also explore other eco-friendly initiatives, such as renewable energy procurement and carbon offset programs in an effort to further reduce environmental impact of cloud storage.
Additional Resources:
- For more information on Wasabi’s work with Zero Circle, visit wasabi.com/sustainability.
- To try Zero Circle’s invoiced-based carbon footprint calculator for Wasabi, visit https://cust.zerocircle.eco/wasabi.
- Join Wasabi, Zero Circle, and 451 Research July 16 at 1 p.m. ET/10 a.m. PT to learn how establishing sustainability goals for IT can help your business meet regulatory compliance more quickly. Read more details here.
About Zero Circle
Zero Circle is a green finance marketplace that simplifies access to green capital for mid-tier businesses. Its AI-powered platform streamlines sustainability assessments and reporting and automates financial and sustainability KPIs to incentivize green financing. The company helps its customers finance and build sustainable practices by tracking, managing, and reporting sustainability and financial performance with lenders, partners, and customers.
Click here to learn more about Zero Circle or follow them on LinkedIn and Twitter.
About Wasabi Technologies
Recognized as one of the technology industry’s fastest growing companies, Wasabi is on a mission to store the world's data by making cloud storage affordable, predictable and secure. With Wasabi, visionary companies gain the freedom to use their data whenever they like without being hit with unpredictable fees or vendor lock-in. Instead, they’re free to build best-of-breed solutions with the industry’s fastest-growing ecosystem of independent cloud application partners. Customers and partners all over the world trust Wasabi to help them put their data to work so they can unlock their full potential. Visit wasabi.com to learn more.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240710254246/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom